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Agonists that deplete intracellular Ca2+ stores also activate Ca2+
entry, although the mechanism by which store release and Ca2+ in-
flux are linked is unclear. A potential mechanism involves ‘store-
operated channels’ that respond to depletion of the intracellular
Ca2+ pool. Although SOCE (store-operated Ca2+ entry) has been
considered to be the principal route for Ca2+ entry during hormo-
nal stimulation of non-electrically excitable cells, recent evidence
has suggested that alternative pathways activated by metabolites
such as arachidonic acid are responsible for physiological Ca2+
influx. It is not clear whether such messenger-activated pathways
exist in all cells, whether they are truly distinct from SOCE and
which metabolites are involved. In the present study, we demon-
strate that HeLa cells express two pharmacologically and mechan-
istically distinct Ca2+ entry pathways. One is the ubiquitous
SOCE route and the other is an arachidonate-sensitive non-SOCE.
We show that both these Ca2+ entry pathways can provide long-
lasting Ca2+ elevations, but that the channels are not the same,
based on their differential sensitivity to 2-aminoethoxydiphenyl
borate, LOE-908 {(R,S)-(3,4-dihydro-6,7-dimethoxy-isochinolin-
1-yl)-2-phenyl-N,N-di[2-(2,3,4-trimethoxyphenyl)ethyl]acetamid
mesylate} and gadolinium. In addition, non-SOCE and not SOCE
was permeable to strontium. Furthermore, unlike SOCE, the
non-SOCE pathway did not require store depletion and was not
sensitive to displacement of the endoplasmic reticulum from the
plasma membrane using jasplakinolide or ionomycin pretreat-
ment. These pathways did not conduct Ca2+ simultaneously due to
the dominant effect of arachidonate, which rapidly curtails SOCE
and promotes Ca2+ influx via non-SOCE. Although non-
SOCE could be activated by exogenous application of arachi-
donate, the most robust method for stimulation of this pathway
was application of the widely used calmodulin antagonist
calmidazolium, due to its ability to activate phospholipase A2.
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INTRODUCTION
Calcium (Ca2+) is a universal and versatile intracellular messenger
that regulates a diverse range of cellular processes [1]. Cells have
access to two sources of calcium, finite stores located in intra-
cellular organelles and a more substantial pool of extracellular
Ca2+. In many cells types, release of Ca2+ from intracellular stores
leads to the activation of a Ca2+ influx pathway denoted as SOCE
(store-operated Ca2+ entry) [2]. This mechanism for promoting
Ca2+ entry is responsible for replenishing depleted intracellular
stores and prolonging cellular Ca2+ signals [3]. The molecular
identity of the channels responsible for SOCE and their precise
mechanism of activation are unclear. The probable candidates are
members of the TRPC (canonical transient receptor potential)
family [3,4]. Several studies support this hypothesis and have
shown that the expression or ablation of various TRPC isoforms
can modulate SOCE responses (see e.g. [5–7]).
A prominent model for the stimulation of TRPs during SOCE
activation proposes a direct interaction between these plasma
membrane channels and Ca2+ release channels on the intracellular
stores. The latter would serve to sense a decrease in luminal
Ca2+ concentration, and via a conformational change transmit this
information to promote SOCE channel opening [2,3,8,9]. A direct
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interaction between TRPs and two families of intracellular
Ca2+ release channel, Ins(1,4,5)P3Rs (inositol 1,4,5-trisphosphate
receptors) and RyRs (ryanodine receptors) has been demonstrated
[10,11] (see [3,12] for reviews). When the Ca2+ concentration
on the luminal domain of Ins(1,4,5)P3Rs or RyRs is sufficiently
low, this interaction can lead to TRP channel activation. Inter-
ventions that prevent the coupling of intracellular channels with
TRPs, using either peptides that prevent the interaction (see e.g.
[13]) or formation of a subplasmalemmal actin barrier [14,15],
inhibit SOCE activation.
SOCE can be readily demonstrated in almost all non-electri-
cally excitable cells and in some excitable cells after hormonal/
neurotransmitter stimulation or depletion of intracellular Ca2+
stores using SERCA (sarcoplasmic/endoplasmic-reticulum
Ca2+-ATPase) inhibitors, such as thapsigargin [2,3,9,12]. The
broad expression of the SOCE pathway has led to it being con-
sidered a prominent mechanism for Ca2+ entry into cells after Ca2+
pool discharge. However, it is becoming increasingly apparent that
stimulation of cells with hormones that invoke the production of
Ca2+-releasing messengers not only activates SOCE, but can also
promote additional Ca2+ entry pathways [16,17].
When Ins(1,4,5)P3 is produced after phosphoinositide hydro-
lysis, there is a concomitant production of DAG (diacylglycerol).
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Unlike water-soluble Ins(1,4,5)P3, DAG stays in the plane of the
plasma membrane where it can activate PKC (protein kinase C)
or is metabolized further. Both PKC and DAG (or membrane-
permeant analogues) have been demonstrated to cause Ca2+ influx
distinct from SOCE in some cell types [18,19]. Furthermore,
other messengers resulting from DAG metabolism, including
AA (arachidonic acid) and leukotrienes, activate non-SOCE Ca2+
influx [20–22]. The molecular target of these messengers is not
established, although TRPC isoforms have again been implicated.
Although there are an increasing number of reports demonstrating
significant Ca2+ influx via non-SOCE, at present, it is not clear
whether all cells employ a non-SOCE mechanism, and if so, in
response to which messenger. Probably, the best-characterized
non-SOCE activator is AA. Studies from both the Shuttleworth
[21] and Taylor [20] labs have demonstrated pathways for AA-
stimulated Ca2+ entry that are clearly distinct from SOCE.
CaM (calmodulin) plays a critical role in transducing the effects
of cytosolic Ca2+ signals on cellular processes. It is also involved
in the regulation of many channels that generate Ca2+ signals. For
example, two of the most prominent mechanisms for releasing
intracellular Ca2+ stores, via Ins(1,4,5)P3Rs and RyRs, have been
demonstrated to be regulated by CaM [23,24]. For Ins(1,4,5)P3Rs
this is a largely negative effect, whereas for RyRs CaM can
mediate both inhibition and activation (see [25,26] for reviews).
CaM has also been demonstrated to modulate negatively Ca2+
influx through SOCE and TRP channels [27–30].
A common approach in investigating the action of CaM has
been to use membrane-permeant pharmacological antagonists
such as calmidazolium, W-7 [N-(6-aminohexyl)-5-chloro-1-naph-
thalenesulphonamide] and TFP (trifluoperazine). However, these
agents have been shown to cause robust Ca2+ signals albeit through
unknown mechanisms. Calmidazolium, for example, has been
shown to cause Ca2+ release and Ca2+ entry in Dictyostelium
[31], platelets [32], thyroid FRTL-5 cells [33], Madin–Darby
canine kidney cells [34] and HL-60 cells [35]. These responses
could be consistent with CaM causing a tonic inhibition of
Ca2+ channels, which is relieved during activation or application
of CaM antagonists.
We investigated the mechanism by which agents such as calmi-
dazolium triggered Ca2+ increases using HeLa cells. Calmidazol-
ium was capable of evoking Ca2+ signals that fully mimicked those
stimulated by Ins(1,4,5)P3-generating agonists in all respects
except for the pathway through which Ca2+ influx occurred, i.e.
via non-SOCE and not via SOCE.
MATERIALS AND METHODS
HeLa cell culture
HeLa cell culture was performed as described previously [36]. All
experimental procedures were performed at room temperature
(20–22 ◦C). Before imaging, the culture medium was replaced
with an EM (extracellular medium) containing (mM): NaCl,
121; KCl, 5.4; MgCl2, 0.8; CaCl2, 1.8; NaHCO3, 6; D-glucose,
5.5; Hepes, 25 (pH 7.3). Histamine, calmidazolium, U73122 and
thapsigargin were obtained from Sigma. Fura 2 was obtained
from Molecular Probes (Eugene, OR, U.S.A.). Statistics were
performed using Student’s t test (GraphPad Prism, San Diego,
CA, U.S.A.).
Video imaging
Measurement of cytosolic Ca2+ in HeLa cells was performed by
monitoring fura 2 fluorescence of cells adhered to glass cover-
slips using either a Spex or a PerkinElmer imaging system. Fura 2
was loaded into the cells by incubation with 2 µM fura 2 acet-
oxymethyl ester (30 min incubation followed by a 30 min period
for de-esterification). For the Spex system, cells on coverslips
were mounted on a Nikon Diaphot inverted epi-fluorescence
microscope. Fluorescent images were obtained by alternate 40 ms
excitations at 340 and 380 nm using twin xenon arc lamps each
coupled with a spex monochrometer (Spex Industries, Edison,
NJ, U.S.A.), with the wavelengths being switched by a rotating
chopper mirror (Glen Creston Instruments, Stanmore, U.K.).
Emission signals at 510 nm were collected using an intensified
charge-coupled device video camera (Photonics Science,
Robertson, U.K.) and filtered with a 200 ms time constant (Spex
system) before off-line storage for analysis using an Imagine
image processing system (Synoptics, Cambridge, U.K.).
With the PerkinElmer system, a single glass coverslip with
adherent cells was mounted on the stage of a Nikon Diaphot 300
inverted epi-fluorescence microscope coupled with a xenon arc
lamp (Nikon, Tokyo, Japan) light source. Fluorescence images
were obtained with alternate excitations at 340 and 380 nm,
selected for using either a Sutter filter wheel (340HT15 and
380HT15; Sutter Industries, Novarta, CA, U.S.A.) or a Spectra-
master II monochrometer. Emitted light was filtered at 510 nm
and collected by a cooled Astrocam digital camera. The acquired
images were stored and subsequently processed off-line with
Ultraview software (PerkinElmer LifeSciences, Great Shelford,
Cambridge, U.K.).
Mn2+ entry was measured indirectly by recording the quench
of fura 2 fluorescence when excited at 360 nm. To minimize the
effect of contaminating Ca2+, Mn2+-containing Hepes buffer was
supplemented with 1 mM EGTA and the Mn2+ concentration
was adjusted to avoid chelation (2 mM Mn2+ and free Mn2+
∼ 1 mM). MaxChelator (http://www.stanford.edu/∼cpatton/
maxc.html) was used to match free and total chelator and metals
in all solutions containing Mn2+, Gd3+ and Sr2+.
Results are expressed as means +− S.E.M. Representative traces
are shown for most of the experiments. These depict the most
consistent pattern of response from multiple cells imaged in at
least three independent experiments, with experiments repeated
on different days. Statistical significance was calculated using
Student’s t test.
Expression of type 1 Ins(1,4,5)P3 5′-phosphatase
The cDNA encoding the type 1 Ins(1,4,5)P3 5′-phosphatase was
amplified by PCR from a cDNA clone kindly provided by
Professor C. Erneux (Universite´ Libre de Bruxelles, Brussels,
Belgium) and subcloned into pdc515-EGFP-C1 (where EGFP
stands for enhanced green fluorescent protein). All constructs
were transiently transfected using GeneJuiceTM (Novagen,
Nottingham, U.K.), according to the manufacturer’s instructions.
Briefly, 24 h before transfection, cells were seeded on to 22 mm
glass coverslips at 50–80% confluency. Cells were incubated
for 24 h post-transfection at 37 ◦C, in 5% CO2 atmosphere with
saturated humidity to allow expression of the construct. GFP-
tagged actin was transfected into cells using the same procedure.
Jasplakinolide treatment
To stimulate cortical actin polymerization, cells were incubated
for 30 min at 22 ◦C, with 10 µM jasplakinolide in nominally
Ca2+ free solution. To confirm the effect of jasplakinolide on
actin rearrangement, images of cells expressing GFP-tagged actin
were acquired using a Bio-Rad MRC1024 confocal laser-scanning
microscope (×60 objective; 1.4 NA). GFP was excited using a
488 nm laser line and emission was collected through a 505 nm
long-pass filter. Optical sections were taken every 0.4 µm.
c© 2004 Biochemical Society
Arachidonate-mediated Ca2+ influx 931
Figure 1 Characterization of calmidazolium-evoked Ca2+ transients
(A) Ca2+ mobilization and entry induced by calmidazolium in HeLa cells are depicted. Cells were perfused with 10 µM calmidazolium in a nominally Ca2+-free medium before being perfused
with 10 µM calmidazolium in the presence of extracellular Ca2+. (B) Reversibility of cytosolic Ca2+ increase activated by a maximal calmidazolium concentration (2 min application followed by
a 12 min continuous wash) is shown. The concentration–response relationship for calmidazolium-induced Ca2+ signalling is depicted in (C). To distinguish the concentration dependence for
calmidazolium-mediated SOCE activation versus stimulation of the non-SOCE pathway, 100 µM 2-APB was added as shown in the key. In the presence of 2-APB and absence of extracellular
Ca2+ (denoted Ca2+o in the Figure), calmidazolium had a negligible effect on cellular Ca2+. Results indicate means +− S.E.M. for three independent experiments with at least ten cells analysed per
experiment for each condition. (D, E) Overlap between the histamine- and calmidazolium-releasable Ca2+ pool. The traces in (A, B, D and E) were obtained from single HeLa cells and are typical of
at least 20 cells analysed in three independent experiments.
Image analysis and processing were performed with the public
domain software ImageJ (NIH, http://rsb.info.nih.gov.ij).
Preparation and storage of AA
Porcine liver AA (Na+ salt; Calbiochem) was dissolved in MilliQ
water as a concentrated stock solution before being dispensed in
aliquots; they were then frozen and stored at −20 ◦C in a light-
resistant container. Before use, an aliquot of AA was diluted to
the required concentration by addition of EM containing 0.1%
DMSO (to aid membrane permeability). All samples of AA were
kept in the dark and on ice to suppress oxidation.
Use of Ba2+ as a Ca2+ surrogate
For some experiments, Ba2+ was used to monitor cation entry in
place of Ca2+. Ba2+ had been used in previous studies as a Ca2+
surrogate to provide a measure of unidirectional cation flux, since
it was poorly sequestered by intracellular Ca2+ pumps or extruded
from cells. Increases in cytosolic Ba2+ were monitored using fura 2
as described above, using the same excitation and emission
settings as for Ca2+. The results are presented as uncalibrated
ratio (emission at 340 nm/excitation at 380 nm) units.
For the experiments shown in Figure 8, Ba2+ was employed
simply because we could not use calcium with ionomycin-
treated cells, since it would be impossible to identify Ca2+ that
entered cells through the ionophore or via SOCE/non-SOCE. In
our experiments, Ba2+ did not permeate into cells via ionomycin.
RESULTS
CaM antagonist calmidazolium evokes calcium release
and activates a non-SOCE
CaM has been proposed to suppress the activation of both
Ins(1,4,5)P3Rs and SOCE channels. A common method of
antagonizing the action of CaM is to use membrane-permeant
pharmacological antagonists, such as calmidazolium, W-7 and
TFP. Consistent with the idea that CaM antagonists relieve CaM-
dependent inhibition of Ca2+ channels, these compounds have
all been demonstrated to cause Ca2+ signals within intact cells.
However, it has not been established whether their cellular target
is CaM or other processes involved in Ca2+ signal transduction.
We therefore determined whether there was a direct effect of CaM
antagonists on the activity of Ins(1,4,5)P3Rs and SOCE channels.
We initially concentrated on the action of the imidazole compound
calmidazolium, since this has been widely used to abrogate effects
of CaM and has also been shown to activate Ca2+ mobilization
and Ca2+ entry.
When applied in Ca2+-free medium, calmidazolium evoked a
rapid transient increase in cytosolic Ca2+ (Figure 1A; average
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Figure 2 Activation of Ca2+ entry by calmidazolium does not require Ca2+ store release
(A–C) Lack of Ca2+ release after calmidazolium application if Ins(1,4,5)P3 production or Ins(1,4,5)P3Rs are inhibited using pharmacological agents. (D, E) A similar inhibition of calmidazolium-
induced Ca2+ release was observed in cells overexpressing the Ins(1,4,5)P3 metabolizing 5′-phosphatase enzyme (denoted 5 P′ase in the Figure). Note that the control traces in (D) have
been shifted upwards by 50 nM to allow clearer visualization of the responding control and non-responding test traces. There was no difference in the basal Ca2+ levels between control and
5′-phosphatase-expressing cells. Representative traces from two individual cells are shown for both the control and 5′-phosphatase-expressing cells. Although overexpression of the 5′-phosphatase
enzyme blocks calmidazolium-induced Ca2+ release, the traces in (E) show that calmidazolium could still activate Ca2+ influx. The responses of two representative 5′-phosphatase-expressing cells
are shown. Histamine was added during the experiment to confirm the abolition of Ins(1,4,5)P3-induced Ca2+ signals by the 5′-phosphatase expression. The traces in (A–C) were obtained from
single HeLa cells and are typical of at least 20 cells analysed in three independent experiments.
peak response 462 +− 44 nM; n = 126 cells), which was followed
by robust calcium entry when extracellular calcium was replaced
(average response 935 +− 71 nM; n = 126 cells). Effects of cal-
midazolium were reversible, since pulsatile application caused
repetitive Ca2+ responses (Figure 1B). Calmidazolium evoked
concentration-dependent Ca2+ increases (Figure 1C), with all cells
responding to doses of calmidazolium >2 µM (n > 600 cells from
20 independent experiments). At concentrations 1 µM calmid-
azolium, global Ca2+ responses were not observed. Instead, sub-
cellular Ca2+ transients that we, and others, have described as
‘Ca2+ puffs’ [37] were evoked (results not shown).
The Ca2+ pool mobilized by calmidazolium overlapped largely
with the Ins(1,4,5)P3-sensitive Ca2+ store. Application of a
maximal histamine concentration (100 µM) in Ca2+-free medium
to deplete the Ins(1,4,5)P3-sensitive Ca2+ pools decreased the
response to a subsequent addition of calmidazolium (10 µM) usu-
ally to a single low-amplitude Ca2+ transient (Figure 1D). In the
reciprocal experiment, application of a maximal calmidazolium
concentration (10 µM) in Ca2+-free medium substantially reduced
the magnitude of response observed with an ensuing histamine
challenge (Figure 1E). When applied to naive cells, 100 µM hista-
mine evoked an average peak Ca2+ increase in 763 +− 12 nM (n =
49 cells). After calmidazolium treatment, histamine responses
were reduced to 283 +− 16 nM (n = 37 cells). With cells in Ca2+-
free medium, but not Ca2+-containing medium, calmidazolium
frequently triggered Ca2+ oscillations that were similar in rise
time and duration to those observed during hormonal stimulation
(cf. Figures 1D and 1E).
Calmidazolium-activated Ca2+ signals described above were
comparable in almost all respects with typical responses triggered
by hormonal stimulation of HeLa cells [38]. Similar to hormonal
agonists, it appeared that calmidazolium was capable of releasing
the Ins(1,4,5)P3-sensitive Ca2+ store and triggering Ca2+ entry. To
determine the mechanism by which calmidazolium could activate
Ca2+ release, we examined the effects of well-known inhibitors
of PLC (phospholipase C) and Ins(1,4,5)P3Rs. Application of the
PLC inhibitor U73122 at a concentration that blocks agonist-
evoked Ca2+ signalling in HeLa cells [39] completely inhibited
Ca2+ mobilization by calmidazolium (Figure 2A). Whereas all
cells responded to 10 µM calmidazolium under control conditions
(see above), no cells displayed Ca2+ mobilization in response to
10 µM calmidazolium in the presence of U73122. The inactive
analogue U73343 did not prevent Ca2+ release activated by
10 µM calmidazolium (n = 60 cells; results not shown). 2-APB
(2-aminoethoxydiphenyl borate), which we have demonstrated
previously to inhibit Ins(1,4,5)P3-induced Ca2+ release in HeLa
cells [40], also prevented Ca2+ mobilization by calmidazolium
(Figure 2B). Caffeine, which acts as a combined blocker of PLC
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Figure 3 LOE-908 inhibits calmidazolium-induced Ca2+ entry, but not SOCE
(A–D) The responses of individual HeLa cells to the agents are denoted by the bars. For each panel, the response is typical of at least 20 cells analysed in three independent experiments.
and Ins(1,4,5)P3Rs, also prevented calmidazolium-evoked Ca2+
release (Figure 2C). Heterologous expression of the 5′-phos-
phatase enzyme, which degrades Ins(1,4,5)P3 to the non-Ca2+
releasing metabolite Ins(1,4)P2, prevented Ca2+ mobilization in
response to either a maximal histamine concentration (100 µM)
or a maximal calmidazolium dose (10 µM; Figure 2D). Since
calmidazolium has been shown previously to activate PLC activity
[34], the simplest interpretation of the results presented above
is that calmidazolium mobilizes Ca2+ stores by activation of
PLC. Therefore, with respect to Ca2+ release from Ins(1,4,5)P3Rs,
calmidazolium mimics an Ins(1,4,5)P3-generating agonist.
Although the mobilization of Ins(1,4,5)P3-sensitive Ca2+ stores
by calmidazolium can be ascribed to activation of PLC, the entry
of Ca2+ in calmidazolium-treated cells appears to occur via a dis-
tinct mechanism. None of the agents that blocked calmidazolium-
induced Ca2+ mobilization (Figures 2A–2C) inhibited Ca2+ entry
when Ca2+ was reapplied to cells. In addition, expression of the
5′-phosphatase enzyme to levels that completely abrogated hista-
mine-evoked Ca2+ signals and prevented calmidazolium causing
Ca2+ release (Figure 2D), did not inhibit calmidazolium-in-
duced Ca2+ entry (Figure 2E). Furthermore, similar to previous
results [41], we have demonstrated that 2-APB completely
inhibited SOCE in HeLa cells [40], yet it did not prevent calmi-
dazolium-induced Ca2+ influx (Figure 2B). These results indicate
that calmidazolium activated a Ca2+ entry pathway that was
distinct from that triggered by store depletion.
Calmidazolium-activated non-SOCE is pharmacologically
distinct from SOCE
Calmidazolium induced an additional increase in the plateau Ca2+
level after full SOCE activation by application of a maximal con-
centration of thapsigargin (2 µM; Figure 3A), which was com-
pletely blocked by the cation channel inhibitor LOE-908
{(R,S)-(3,4-dihydro-6,7-dimethoxy-isochinolin-1-yl)-2-phenyl-
N,N-di[2-(2,3,4-trimethoxyphenyl)ethyl]acetamidmesylate}(Fig-
ure 3B). In contrast, LOE-908 gave only a modest inhibition of
Ca2+ entry stimulated by thapsigargin (Figures 3C and 3D).
Gadolinium (Gd3+) has been used previously as a high-affinity
irreversible inhibitor of SOCE (see e.g. [42]). We similarly ob-
served that 1 µM Gd3+ completely blocked Ca2+ influx evoked by
application of thapsigargin (Figure 4A). However, Gd3+ had only a
partial effect on calmidazolium-induced Ca2+ entry when applied
at concentrations 10 µM (Figure 4B). The weak effect of Gd3+
on calmidazolium-evoked bivalent cation entry was also observed
by substituting extracellular Ca2+ with manganese (Mn2+) and by
following the quenching of fura 2 fluorescence as Mn2+ entered the
cells. Calmidazolium evoked a significant increase in the rate of
Mn2+ entry (Figure 4C), which was unaffected by the presence
of Gd3+ (Figure 4D). A further difference in cation sensitivity of
the two influx pathways was observed when Ca2+ in the EM was
substituted by strontium (Sr2+). The SOCE pathway in HeLa cells
did not appreciably conduct Sr2+, whereas Sr2+ entry was readily
detectable after calmidazolium treatment (Figure 4E). A summary
of the pharmacological distinction between SOCE and the Ca2+
entry pathway activated by calmidazolium is shown in Fig-
ure 4(F).
During prolonged activation, SOCE-mediated Ca2+ influx dimi-
nishes despite intracellular Ca2+ stores remaining empty (see
e.g. [43,44]; Figure 5A). This has been demonstrated to be due
to progressive inhibition of the Ca2+ entry pathway and accele-
ration of Ca2+ sequestration [44]. Approx. 20 min after stimulation
with thapsigargin, the cytosolic Ca2+ concentration had returned
to the resting level. Subsequent application of calmidazolium
provoked a steep increase in Ca2+ (Figure 5A), which was
c© 2004 Biochemical Society
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Figure 4 Characteristics of calmidazolium-activated non-SOCE
(A) Complete inhibitory effect of 1 µM Gd3+ on SOCE, with little effect on calmidazolium-evoked non-SOCE is illustrated. The concentration–response relationship for the effect of Gd3+ on SOCE
and non-SOCE-mediated Ca2+ entry is shown in (B). The solid line depicts the effect of Gd3+ on thapsigargin (TG)-evoked SOCE, whereas the broken line illustrates the corresponding effect on
calmidazolium-activated non-SOCE. (C, D) Calmidazolium activated entry of Mn2+ into HeLa cells, despite the presence of Gd3+ at a concentration that completely inhibits SOCE. (E) SOCE pathway
in HeLa cells is not permeable to Sr2+, but entry of this cation can be achieved by application of calmidazolium. A summary of the pharmacological profiles of the SOCE and non-SOCE cation entry
pathways is depicted in (F). The traces shown in this Figure were obtained from individual HeLa cells and are indicative of similar responses in at least 20 cells from three independent experi-
ments.
abolished by LOE-908 (results not shown). By itself, LOE-908
had little effect on the time course of thapsigargin-evoked SOCE
(results not shown). Although the amplitude of both SOCE- and
calmidazolium-evoked Ca2+ entries varied between cells, the
latter pathway generally produced larger Ca2+ signals, as illu-
strated in Figure 5(B). For the experiment depicted in Figure 5(B),
the mean peak amplitudes for Ca2+ entry through SOCE- and cal-
midazolium-sensitive pathway were 117 +− 33 and 275 +− 36 nM
respectively (n = 30; P < 0.002).
In a recent study, Bolotina and co-workers [45] utilized
calmidazolium to activate SOCE in smooth-muscle cells. They
demonstrated that low concentrations of calmidazolium specific-
ally activated SOCE, as judged by complete abolition of Ca2+ in-
flux with 2-APB. At higher concentrations of calmidazolium, they
found that the Ca2+ entry was insensitive to 2-APB. We observed a
similar concentration-dependent action of calmidazolium. 2-APB
suppressed responses to low (2.5 µM), but not high (5 µM),
calmidazolium concentrations (Figure 1C). Similar to Bolotina
and co-workers, we interpret these results as indicating that
calmidazolium has distinct effects at low and high concentrations.
Low concentrations activate SOCE, whereas higher doses switch
the Ca2+ entry to 2-APB-insensitive non-SOCE.
Bolotina and co-workers [45] suggested that low calmidazolium
concentrations activated SOCE in the absence of calcium release.
In contrast, using real-time confocal microscopy, we observed
that Ca2+ release was the earliest response of the cells to calmid-
azolium. As described above, concentrations of 1 µM cal-
midazolium triggered Ca2+ puffs, which can lead to Ca2+ waves
[37]. Therefore the most sensitive response of cells to calmid-
azolium is Ca2+ release, not Ca2+ entry.
Calmidazolium activates the same non-SOCE pathway
as AA in HeLa cells
Various messengers and metabolites have been shown to activate
Ca2+ influx independently of Ca2+ store release, including PKC,
DAG and AA. We therefore used established pharmacological
agents to probe the contribution of these moieties in calmidazol-
ium-activated Ca2+ entry.
Treatment of cells with the PKC activators PMA (1 µM; n =
50 cells) or 1-oleoyl-2-acetyl-sn-glycerol (1 µM; n = 90 cells)
neither caused Ca2+ increase nor prevented Ca2+ response to
calmidazolium when perfused on to cells for up to 30 min. The
DAG lipase inhibitor, RHC-80267, has been used in previous
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Figure 5 Calmidazolium can activate Ca2+ influx after run-down of SOCE
Prolonged activation of SOCE leads to a progressive decrease in Ca2+ to basal levels.
(A) Application of calmidazolium activated Ca2+ entry despite run-down of SOCE is shown.
(B) Method for estimating the relative amplitude of SOCE- and non-SOCE-mediated Ca2+
signals.
studies (see e.g. [20]) to abrogate the release of AA from
DAG and thus prevent the subsequent activation of an AA-
sensitive Ca2+ influx. However, pretreatment of HeLa cells with
RHC-80267 (50 µM; 15 min preincubation; n = 25 cells) did not
affect the amplitude or extent of calmidazolium-induced Ca2+
entry.
Mammalian cells express a diverse array of PLA2 (phospholi-
pase A2) subtypes [46]. In the present study, three PLA2 inhibitors,
ACA [N-(p-amylcinnamoyl) anthranillic acid], isotetrandrine and
AACOCF3 (arachidonyltrifluoromethyl ketone), were used to in-
vestigate the role of PLA2 in the activation of Ca2+ entry by calmi-
dazolium in HeLa cells. Isotetrandrine, an inhibitor of G-protein-
linked PLA2 (10 µM; 20 min preincubation; [21]) had no effect
on calmidazolium-induced Ca2+ signals. Similarly, AACOCF3,
a selective inhibitor of cytosolic (85 kDa) PLA2 (100 µM;
20 min preincubation) did not affect Ca2+ signals evoked by
calmidazolium. In contrast, 10 µM ACA, which blocks Ca2+-
independent PLA2 activity [47], rapidly and reversibly inhibited
both Ca2+ mobilization and Ca2+ entry evoked by calmidazolium
(Figure 6A). The ability of ACA to prevent calmidazolium-in-
duced Ca2+ signals implicates AA or one of its metabolites as the
critical messenger(s) underlying the activation of the non-SOCE
Ca2+ influx pathway described above. Consistent with the notion
that calmidazolium stimulates PLA2 and that the resultant AA
production activates Ca2+ signalling, direct application of 10 µM
AA to cells in the presence of ACA evoked both Ca2+ mobilization
and Ca2+ entry (Figure 6B).
To confirm that AA and calmidazolium were activating the
same Ca2+ influx pathway, we examined the pharmacological
profile and cation sensitivity of the Ca2+ signals evoked by direct
AA application. Similar to calmidazolium, Ca2+ entry stimulated
by 10 µM AA was not inhibited by 100 µM 2-APB (Figure 7A)
or 10 µM U73122 (Figure 7B) or sensitive to expression of the 5′-
phosphatase enzyme (n = 10 cells). Similar to the calmidazolium-
provoked Ca2+ entry after run-down of SOCE (Figure 5A), AA
Figure 6 Calmidazolium-induced Ca2+ signalling is inhibited by the Ca2+-
independent PLA2 inhibitor ACA
(A) The reversible inhibition of calmidazolium-evoked Ca2+ release and influx by ACA is
depicted. (B) That AA could still release Ca2+ and activate non-SOCE in the presence of ACA,
indicating that the PLA2 inhibitor was not blocking non-SOCE channels is illustrated. The
traces are taken from individual cells and are typical of at least 30 cells from three independent
experiments.
evoked a substantial Ca2+ entry after the decrease in SOCE (Fig-
ure 7C), and this AA-induced Ca2+ entry was completely inhibited
by LOE-908 (30 µM; n = 35 cells). The AA-activated pathway
was also permeable to Sr2+ (Figure 7D) and not blocked by acute
addition of 1 µM Gd3+ (n = 120 cells). In all respects, the Ca2+
influx pathway activated by AA resembled that observed with
calmidazolium stimulation. Neither linolenic acid (n = 60 cells)
nor linoleic acid (n = 32 cells) activated Ca2+ influx.
Although the experiments presented above indicate that AA
production can stimulate the non-SOCE pathway, they do not
implicate AA itself as the sole activator since it can be readily
metabolized. We therefore examined the effect of inhibiting
pathways responsible for AA metabolism. Lipoxygenase and
cyclo-oxygenase enzymes convert AA into leukotrienes and pros-
taglandins, prostacyclins and thromboxanes respectively. In-
cubation of cells with the cyclo-oxygenase inhibitor indomethacin
(10 µM; 25–90 min incubation in different experiments) did not
alter basal Ca2+ levels or prevent Ca2+ signals evoked by cal-
midazolium (n = 45 cells). Similarly, the lipoxygenase inhibitor
aspirin (100 µM; 30–90 min incubation in different experi-
ments) had no effect (n = 30 cells). Finally, metabolism of AA via
mono-oxygenases was prevented by using 100 µM metyrapone,
which also did not alter Ca2+ mobilization or Ca2+ influx in
response to calmidazolium (n = 20 cells). Calmidazolium belongs
to a family of substituted imidazole compounds including eco-
nazole and miconazole. These compounds have a similar structure
to calmidazolium, and may also affect CaM, although they are
more commonly employed as inhibitors of cytochrome P450
mono-oxygenases. As with calmidazolium, 20 µM econazole and
20 µM miconazole evoked Ca2+ mobilization and Ca2+ entry. Co-
application of maximal concentrations (10 µM calmidazolium,
20 µM econazole and 20 µM miconazole) of these imidazole
compounds indicated that their Ca2+ responses were not additive
(results not shown), suggesting that they activated the same Ca2+
influx pathway.
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Figure 7 AA activates a non-SOCE pathway in HeLa cells
The panels in this Figure depict the action of AA in evoking Ca2+ influx with a similar pharmacology to calmidazolium-induced non-SOCE. The traces in (A–D) are taken from individual cells and
are representative of at least 30 cells from three independent experiments for each panel.
Mechanistic differences between SOCE- and
calmidazolium-activated non-SOCE
To distinguish further between SOCE and the AA-activated Ca2+
entry pathway in HeLa cells, we examined the effect of remod-
elling the cytoskeleton to produce a cortical actin deposition.
This technique was used previously to inhibit SOCE activation
[14,15,48]. Reorganization of the actin cytoskeleton was achieved
by incubating HeLa cells with jasplakinolide (10 µM; 30 min
preincubation), and monitored by confocal imaging of EGFP–
actin-transfected cells. In control cells, there was a largely homo-
geneous pool of fluorescence, reflecting monomeric proteins, but
with fluorescent stress fibres also visible. After treatment with
jasplakinolide, the EGFP-tagged actin redistributed to the sub-
plasmalemmal region of cells (Figure 8A). This treatment
abolished the entry of barium (Ba2+), which was used as a slowly
permeant surrogate for Ca2+ through the SOCE pathway (Fig-
ure 8B). However, it did not prevent Ba2+ entry stimulated by
calmidazolium (Figure 8B).
Similar to previous results [49], we have observed that
incubation of cells with ionomycin causes retraction of the ER
(endoplasmic reticulum) from the plasma membrane and frag-
mentation into discrete vesicles [50]. In Ca2+-containing medium,
such ionomycin-induced ER fragmentation and retraction occurs
within approx. 5 min to 100% of cells examined (n > 500).
Since the entry of Ca2+ itself cannot be measured in cells where
ionomycin is present, we examined the effect of ER disruption on
Ca2+ entry using Ba2+. Despite the fact that ionomycin discharges
the ER Ca2+ store and thus should activate SOCE, Ba2+ did not
appear to permeate into ionomycin-treated cells by any detectable
level. In contrast, addition of 10 µM calmidazolium stimulated
Ba2+ entry significantly. These results indicate that the status and
proximity of the ER to the plasma membrane can modulate Ca2+
entry through SOCE, but not the Ca2+ influx pathway activated
by calmidazolium.
Effects of W-7 and TFP on Ca2+ signalling
We examined the effects of other structurally unrelated CaM
antagonists to explore the possibility that activation of the non-
SOCE pathway was somehow linked to their common action of
CaM inhibition. In the absence of extracellular Ca2+, both 300 µM
W-7 and 10 µM TFP induced Ca2+ release from intracellular
stores, which was followed by Ca2+ entry when extracellular Ca2+
was restored (results not shown). Unlike calmidazolium, W-7 was
capable of releasing Ca2+ stores despite the presence of 100 µM
2-APB and activate Ca2+ entry in the presence of either 2-APB
or LOE-908. TFP activated an LOE-908-sensitive Ca2+ influx,
but unlike the substantial and robust Ca2+ influx signals evoked
by calmidazolium, TFP triggered highly variable modest Ca2+
changes (results not shown). The distinct characteristics of the
Ca2+ signals evoked by the CaM antagonists suggests that they
have different modes of action, and that their ability to increase
cytosolic Ca2+ is not due to their common ability to antagonize
CaM.
DISCUSSION
Previous studies have demonstrated that application of CaM
antagonists elicit Ca2+ signals, and proposed that this is due to
relief of CaM-dependent Ca2+ channel inhibition. We similarly
observed that calmidazolium evoked robust Ca2+ signals, but
found that this action was due to stimulation of PLC and PLA2.
Calmidazolium-evoked responses in HeLa cells closely mimicked
the profile of Ca2+ signals evoked by a PLC-coupled agonist
(Figure 1). The release of Ca2+ from intracellular stores was
blocked by U73122 and caffeine (Figure 2), established antag-
onists of PLC-mediated Ins(1,4,5)P3 production. Furthermore,
calmidazolium released Ca2+ from the same pool as histamine
(Figures 1D and 1E), in an Ins(1,4,5)P3-dependent manner (Fig-
ure 2D). Activation of PLC and production of Ins(1,4,5)P3
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Figure 8 Cortical actin deposition or ionomycin-induced ER fragmentation
blocks SOCE, but not calmidazolium-evoked non-SOCE
HeLa cells were treated with jasplakinolide as described in the Materials and methods section to
induce the redistribution of actin from the cell centre to the periphery. The effect of jasplakinolide
treatment is shown in (A). The left- and right-hand sides of the panel depict cells before and
after jasplakinolide treatment respectively. Two-dimensional images and axial projections are
shown to indicate the redistribution of actin. The axial projection was taken across the portion
of the image between the white arrowheads. (B) Effect of pretreating cells with jasplakinolide or
ionomycin on SOCE and their ineffectiveness on non-SOCE. After incubation with jasplakinolide
or control buffer, the cells were stimulated with 1 µM thapsigargin in Ca2+-free medium for
5 min to activate SOCE. For the ionomycin-treated cells, thapsigargin was not added since
the ionophore by itself should have been sufficient to deplete the Ca2+ stores and activate
SOCE.
therefore appears to underlie the release of intracellular Ca2+
stores by calmidazolium.
In addition to stimulation of PLC, calmidazolium activated a
non-SOCE pathway. This Ca2+ entry mechanism was demon-
strably different from SOCE based on its pharmacological profile
(Figures 2A–2C, 3B and 4A–4D), ion selectivity (Figure 4E), lack
of sensitivity to remodelling actin in a cortical ring (Figure 8B)
or ionomycin-induced fragmentation and retraction of the ER
(Figure 8B). The activation of non-SOCE by calmidazolium
appeared to be due to stimulation of PLA2 since inhibition of
this enzyme completely prevented Ca2+ influx in response to
calmidazolium. Furthermore, the product of PLA2 activation, AA,
was capable of stimulating a non-SOCE pathway with exactly
the same pharmacological profile (Figures 7A and 7B) and ion
selectivity (Figure 7D) as calmidazolium itself. Inhibition of
lipoxygenase, cyclo-oxygenase and mono-oxygenase pathways
did not alter the ability of calmidazolium to trigger Ca2+ influx,
suggesting that AA is the messenger responsible for the activation
of non-SOCE.
Of all the metabolites demonstrated to activate non-SOCE,
possibly the most commonly effective moiety is AA. This polyun-
saturated fatty acid has been demonstrated to activate Ca2+ influx
in a variety of different cell types [7,20–22,51,52]. In the present
study, we observed that addition of AA to cells rapidly inhibited
SOCE and switched the mode of Ca2+ influx to LOE-908-
sensitive non-SOCE (Figure 7C). Calmidazolium also switched
the pathway of Ca2+ influx from SOCE to LOE-908-sensitive non-
SOCE (Figure 3B), although it caused a more rapid changeover
when compared with AA. These results suggest that AA is a
dominant Ca2+ influx effector over the SOCE mechanism, and that
the pathways do not function in an additive manner. We found
that both calmidazolium and AA could activate Ca2+ entry despite
an ongoing SOCE response (e.g. Figures 3A and 7C). Addition
of either of the compounds at the peak or plateau phase of a
thapsigargin response, triggered non-SOCE, suggesting that this
mechanism is not particularly sensitive to ambient Ca2+ levels. It
therefore appears to us that the exclusivity of these Ca2+ influx
pathways reflects the dominance of AA, it shuts off SOCE and
promotes non-SOCE.
Our results have some similarity to the recent study of Bolotina
and co-workers [45], who demonstrated that low concentrations
of calmidazolium stimulated 2-APB-sensitive SOCE, whereas
higher doses of calmidazolium invoked a 2-APB-insensitive Ca2+
influx. Similar to the results of the present study, Bolotina
and co-workers suggested that the key target of calmidazolium
was PLA2. They focused on the effects of low calmidazolium
concentrations and suggested that the lysophospholipids produced
by PLA2 caused SOCE activation. We have characterized the Ca2+
entry generated by higher concentrations of calmidazolium and
found that AA probably plays a significant role. Calmidazolium
therefore appears to be capable of activating both SOCE and non-
SOCE depending on its concentration. Both effects stem from
the activation of PLA2, but may depend on the balance between
lysophospholipids and AA.
Although they are widely used, cellular actions of CaM
antagonists are not fully resolved. The consistent observation that
they increase cytosolic Ca2+ is problematic considering that they
are generally used to antagonize downstream actions of Ca2+.
Concentration-dependent Ca2+ increases have been reported using
various cell types in response to CaM antagonists including TFP,
W-7, fendiline, chlorpromazine as well as calmidazolium. For
most of these agents, the mechanism by which they cause Ca2+
signals is not known. Calmidazolium is perhaps one of the best
understood and is known to affect Ins(1,4,5)P3Rs [53], SERCA1
Ca2+ pumps [54] and L-type voltage-operated Ca2+ channels [55].
Consistent with our observations, calmidazolium has been demon-
strated to cause Ins(1,4,5)P3 production through activation of
PLC in several cell types (see e.g. [34,56]). Furthermore,
calmidazolium activated Ca2+ release and Ca2+ entry in Madin–
Darby canine kidney cells, with the effects being abolished by the
PLA2 inhibitor aristolochic acid [34].
Accumulating evidence suggests that CaM is a significant regu-
lator of SOCE activity. CaM may prevent Ca2+ entry by interfering
with the physical coupling of Ins(1,4,5)P3Rs and SOCE channels.
C-terminal portions of different TRPCs have been demonstrated
to bind CaM or an N-terminal sequence of Ins(1,4,5)P3Rs in
a mutually exclusive manner [27,57,58]. Displacement of CaM
by short peptides corresponding to the competing region of
Ins(1,4,5)P3Rs leads to activation of TRP channels [30]. CaM
therefore appears to act as a barrier in the activation of
Ca2+ entry by occluding the site through which TRPs and
Ins(1,4,5)P3Rs interact. Consistent with this notion, application of
CaM antagonists (W-7 and TFP) significantly reduced the delay
in development of SOCE after store depletion, whereas increasing
CaM concentration caused the converse [28]. Furthermore, cal-
midazolium was capable of enhancing TRP activity by displacing
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CaM from the site where it prevented interaction with
Ins(1,4,5)P3Rs [30,57]. For Ins(1,4,5)P3Rs, CaM can bind to an
N-terminal region and decrease the ability of Ins(1,4,5)P3 to
activate the channels [24,59]. In addition, CaM may be responsible
for the negative feedback effects of increased cytosolic Ca2+ on
Ins(1,4,5)P3R activation [23]. CaM therefore can provide both a
tonic and a dynamic inhibitory influence on Ca2+ release and entry
in non-electrically excitable cells.
Although we suppose that the ability of calmidazolium to
release Ca2+ and activate non-SOCE was not due to CaM anta-
gonism, we did observe an effect of calmidazolium on SOCE,
which is consistent with the proposed inhibitory action of CaM.
Activation of SOCE by thapsigargin allows the entry of Ca2+
or Ba2+ into HeLa cells. Ba2+ is a useful surrogate, since it is
poorly transported by cellular Ca2+ pumps and therefore provides
a unidirectional measure of cation entry. In the presence of ACA
to prevent activation of non-SOCE, calmidazolium increased the
rate of thapsigargin-stimulated Ba2+ entry into cells by approx.
7-fold. In the absence of calmidazolium, the initial rate of Ba2+
entry was 0.19 +− 0.04 ratio units/min (n = 5; measured using fura
2; see the Materials and methods section). In the presence of
10 µM calmidazolium, the rate of Ba2+ entry was 1.26 +− 0.21 ratio
units/min (n = 6). It therefore appears that calmidazolium does
potentiate SOCE by working as a conventional CaM antagonist.
In summary, we have demonstrated that HeLa cells express two
distinct Ca2+ entry pathways, one regulated by store depletion and
the other by AA. These pathways do not operate simultaneously
due to the dominant effect of AA, which inhibits SOCE and
promotes non-SOCE. The non-SOCE pathway can be directly
activated by exogenous AA application, but in HeLa cells it is also
robustly stimulated by calmidazolium. The effect of cal-
midazolium in promoting Ca2+ release and non-SOCE is not
due to CaM antagonism, but rather due to activation of PLC
and PLA2. At present the function of the non-SOCE pathway in
HeLa cells is not clear. Our attempts to find cellular agonists that
couple with this pathway have so far proved negative. Histamine,
ATP and serum all strongly activate Ca2+ release in HeLa cells,
which is followed by Ca2+ entry. However, the Ca2+ influx was
sensitive to 1 µM Gd3+, which is indicative of SOCE. In addition,
LOE-908 does not affect prolonged Ca2+ oscillations activated by
histamine (results not shown). Calmidazolium can stimulate Ca2+
oscillations, but only in Ca2+-free medium when the non-SOCE
pathway is not transporting Ca2+ into the cells. Therefore, rather
than supporting Ca2+ oscillations, the non-SOCE channel appears
to compromise the ability of HeLa cells to display repetitive Ca2+
spikes.
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